News | Heart Valve Technology | December 02, 2016

Edwards To Acquire Transcatheter Mitral, Tricuspid Valve Repair Company Valtech Cardio

Acquisition enables entry into transcatheter valve repair segment of interventional structural heart

Cardioband, valtech, Edwards Lifesciences, transcatheter mitral repair, transcatheter tricuspid valve repair, transcatheter annuloplasty

An illustration of how the transcatheter Cardioband System can used as a non-surgical form on annuloplasty repair. 


December 2, 2016 — Edwards Lifesciences Corp. announced this week it has agreed to acquire Valtech Cardio Ltd., a privately held company based in Israel and developer of the Cardioband System for transcatheter repair of the mitral and tricuspid valves. The acquisition will give Edwards access to the Cardioband Reconstruction System (Cardioband) for transcatheter repair of the mitral valve and tricuspid valve of the heart. The device technology simulates surgical annuloplasty repairs that reconfigure the shape of the valve annulus to reduce or eliminate valve regurgitation. 

Read the article "Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation," about the Cardioband.

The system utilizes a catheter inserted into the femoral vein and delivered through a transseptal approach across the septum of the heart. The direct annuloplasty system features a unique segmental deployment that conforms to each patient's specific annular geometry, addressing the needs of patients with functional mitral regurgitation. In 2015, the Cardioband transseptal mitral repair system received CE mark approval for European sales. Valtech has also initiated a CE mark trial for the tricuspid application of a similar version of this device, which is intended to reduce tricuspid regurgitation. 

"As we continue to pursue multiple therapies to address the diverse needs of patients affected by heart valve disease, we saw an important opportunity to incorporate Valtech's technologies into our comprehensive heart valve repair and replacement portfolio," said Michael A. Mussallem, Edwards' chairman and CEO.  "We recognize that physicians will likely need a toolbox of options to treat their patients most effectively.  We are very pleased with the progress and future prospects of the multiple internal programs we have underway, and we believe the addition of Valtech's talented team and mitral and tricuspid technologies will present even more opportunities to help patients."

The purchase price of Valtech is $340 million in stock and cash at closing, with the potential for up to $350 million in additional pre-specified milestone-driven payments over the next 10 years.  Prior to the close of the transaction, which remains subject to customary closing conditions and is expected in early 2017, Valtech will spin off its early-stage transseptal mitral valve replacement technology program. Edwards will retain an option to acquire that program and its associated intellectual property.

"We are pleased that Edwards, a global leader in patient focused medical innovations for structural heart disease, has elected to include in its growing portfolio of transcatheter based therapies, the Cardioband system for both mitral and tricuspid valve repair. We believe this will position Cardioband to achieve its full potential as a fundamental breakthrough in the way patients are treated for both mitral and tricuspid regurgitation" said Amir Gross, founder and CEO of Valtech. "On behalf of the entire Valtech organization, I want to thank the many physicians who supported us over the past ten years in the development of the Cardioband platform.”
 
Prior to the closing, Valtech will spin out its early stage Cardiovalve program, and as part of the agreement, Edwards will retain an option to acquire the Cardiovalve program at a later date. Cardiovalve is a transcatheter, transseptally delivered, low-profile, mitral valve replacement (TMVR) system following the Valtech way of delivering surgical based solutions without the risk of surgery. The Cardiovalve platform has an orientation-indifferent structure for reduced implant complexity and was designed from inception to enable transseptal delivery.

Separately, Edwards' Board of Directors has authorized a new share repurchase program to acquire up to an additional $1 billion of the company's outstanding common shares. Edwards also has $277 million remaining of its current $750 million share repurchase program, which was authorized in July 2014. This authorization enables the company to repurchase shares to offset the dilution of the Valtech transaction, and continue executing its share repurchase strategies.

Edwards will provide financial guidance for 2017 and discuss the Valtech transaction further at its annual Investor Conference on Dec. 8.

The Cardioband System is not approved for sale in the United States.

Watch the VIDEO "Transcatheter Tricuspid Valve Repair and Replacement Technologies," and discussion with Rebecca Hahn, M.D.

Read the related article "Advances and Future Directions for Transcatheter Valves - Mitral and tricuspid valve repair technologies now in development.”

For more information: www.Edwards.com, www.valtechcardio.com


Related Content

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

February was a short but busy month in the diagnostic and interventional cardiology world, with a lot of news being ...

Home March 01, 2023
Home
News | Cardiovascular Business

February 17, 2023 — Internationally recognized cardiologist in heart transplantation Jon Kobashigawa, MD, director of ...

Home February 17, 2023
Home
News | Cardiovascular Business

February 9, 2023 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has entered into a long ...

Home February 09, 2023
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is a recap of what DAIC viewers found most interesting during the month of January: 1. A Dietary Supplement Leads ...

Home February 01, 2023
Home
News | Cardiovascular Business

January 24, 2023 — Cardiothoracic surgeon Thomas E. MacGillivray, MD, from MedStar Health, was elected President of The ...

Home January 24, 2023
Home
News | Cardiovascular Business

January 19, 2023 — The volunteers and staff of the American Heart Association and the American Stroke Association are ...

Home January 19, 2023
Home
News | Cardiovascular Business

January 19, 2023 — Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy (IVL) to treat ...

Home January 19, 2023
Home
News | Cardiovascular Business

January 11, 2023 — The Alameda, Calif.-based global healthcare company Penumbra has announced U.S. Food & Drug ...

Home January 11, 2023
Home
News | Cardiovascular Business

January 9, 2023 — CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under ...

Home January 09, 2023
Home
News | Cardiovascular Business

January 9, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the appointment ...

Home January 09, 2023
Home
Subscribe Now